Robert K. Naviaux, MD, PhD, is a Professor in Residence at the University of California, San Diego, California, USA. His work "has focused on the role of mitochondrial DNA replication, copy number regulation, DNA damage, and nucleotide signaling in development, aging, healing and regeneration in mitochondrial mechanisms of disease and development." He was invited to join the Open Medicine Foundation's research team in 2016, following a announcement that the ME/CFS Severely Ill, Big Data Study had a significant result in the area of mitochondria.
Dr. Naviaux directs the Robert Naviaux Laboratory at University of California, San Diego (UCSD) whose work is "divided into two groups: 1) Mitochondrial Mechanisms of Disease and Development, and 2) Evolutionary Systems Biology and Marine Metagenomics." He is founder and co-director of the Mitochondrial and Metabolic Disease Center at UCSD, the co-founder and a former president of the Mitochondrial Medicine Society, as well as, a founding associate editor of the journal, Mitochondrion.
Dr. Naviaux "discovered the cause and created the diagnostic test for Alpers syndrome, a mitochondrial disease... [and] is the director of the first FDA-approved clinical trial to study suramin [an antiparasitic drug] as a treatment for autism."
In May 2016, a study was launched, led by Dr. Naviaux and Dr. Ronald Davis, in collaboration with Dr. Eric Gordon, Dr. Paul Cheney, and the Stanford Genome Technology Center in order "to validate earlier findings of a possible diagnostic signature for ME/CFS by measuring metabolites and to evaluate the contribution of genetics to the variation in observed metabolic signatures in this disease." The initial phase, with a total of 90 participants, has been completed and suggests "the mitochondria is in hypometabolism due to a chronic cell danger response state in ME/CFS patients."
Education[edit | edit source]
- 1994-1997 - Fellowship (Biochemical Genetics, mtDNA Replication), University of California, San Diego Medical Center, San Diego, CA
- 1990-1994 - Postdoctorate (Retrovirology, Gene Therapy), The Salk Institute, La Jolla, CA
- 1986-1990 - Internship and Residency, Internal Medicine, American Board of Internal Medicine (ABIM), Clinical Investigator Pathway, University of California, Davis
- 1986, 1989 - M.D., Ph.D. (Genetics, Virology), Indiana University School of Medicine, Indianapolis, IN
- 1981 - M.S. (Zoology), Indiana University, Bloomington, IN
- 1979 - B.S. (Biological Sciences), University of California, Davis, CA
- 1977-1978 - Undergraduate (Biochemistry), Georg August Universität, Göttingen, Germany
Notable studies[edit | edit source]
- 2017, A robust, single-injection method for targeted, broad-spectrum plasma metabolomics (Full Text)
- 13 Sep 2016, Metabolic features of chronic fatigue syndrome (Full Text)
- 2014, Metabolic features of the cell danger response (Full Text)
- 2008, Mitochondrial control of epigenetics
- 2004, Developing a systematic approach to the diagnosis and classification of mitochondrial disease
Awards and Honors[edit | edit source]
- 2008, Hailey’s Wish Foundation - Hailey’s Hero Award, For Outstanding Research and Clinical Care of children with mitochondrial disease
- 2007, Thomson ESI - Science Citation Index “Fast Moving Front Article”
- 2007, United Mitochondrial Disease Foundation Mitochondrial Medicine - Best Abstract Award
- 2002, Honored in a non-fiction book entitled, Anna’s Friends — Lessons Learned from a Short and Beautiful Life
Talks and interviews[edit | edit source]
- Keynote Speech: The metabolism of the cell danger response, healing, and ME/CFS
- (with Spanish subtitles)
Articles[edit | edit source]
- 2016, "Mitochondria Man Gets His Money and the UK Goes Mega: Chronic Fatigue Syndrome Research Moving Forward"
Online presence[edit | edit source]
- PubMed for Robert Naviaux
- University of California, San Diego Faculty Website
- YouTube talks for Robert Naviaux on autism
- Health Rising Forum for Robert Naviaux
Learn more[edit | edit source]
- Robert Naviaux Laboratory at UC San Diego
- The Significance of Reversing Autism-Like Features in Two Distinct Mouse Models With a Single Drug, Suramin
See also[edit | edit source]
References[edit | edit source]
- Clinical Trial Launched to Assess Safety and Efficacy of Autism Drug Treatment - Newsroom By: Scott LaFee
- Li, Kefeng; Naviaux, Jane C.; Bright, A. Taylor; Wang, Lin; Naviaux, Robert K (2017), "A robust, single-injection method for targeted, broad-spectrum plasma metabolomics", Metabolomics, 13 (122), doi:10.1007/s11306-017-1264-1